Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib

被引：197
|
作者：
Hantschel, Oliver [1 ]
Rix, Uwe [1 ]
Superti-Furga, Giulio [1 ]
机构：
[1] Austrian Acad Sci, Ctr Mol Med, A-1090 Vienna, Austria
来源：
LEUKEMIA & LYMPHOMA | 2008年 / 49卷 / 04期
关键词：
BCR-ABL; imatinib; drug targets; chemical proteomics;
D O I：
10.1080/10428190801896103
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Following the initial success of imatinib as frontline therapy for chronic myeloid leukemia (CML), several second-generation therapeutics have been developed with increased potency and the ability to inhibit the majority of imatinib-resistant mutations. Here, we review the current knowledge about the target specificity of the two new inhibitors nilotinib and dasatinib in comparison to imatinib, including the recent large-scale chemical proteomics screens.
引用
收藏
页码：615 / 619
页数：5
相关论文
共 50 条
  • [21] Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants
    Redaelli, Sara
    Piazza, Rocco
    Rostagno, Roberta
    Sassone, Marianna
    Magistroni, Vera
    Perini, Pietro
    Marega, Manuela
    Boschelli, Frank
    Gambacorti, Carlo
    BLOOD, 2008, 112 (11) : 1105 - 1105
  • [22] Differential Effects of the BCR-ABL-Inhibitors Imatinib, Nilotinib and Dasatinib on NK Cell Reactivity against Chronic Myeloid Leukemia (CML)
    Krusch, Matthias
    Salih, Julia
    Kanz, Lothar
    Salih, Helmut R.
    BLOOD, 2008, 112 (11) : 1098 - 1098
  • [23] Response to dasatinib after imatinib failure according to type of preexisting BCR-ABL mutations.
    Mueller, Martin C.
    Erben, Philipp
    Schenk, Thomas
    Lauber, Stephanie
    Kruth, Jens
    Hoffmann, Jana
    Ernst, Thomas
    Lahaye, Tanja
    Metzgeroth, Georgia
    Acevedo, Michael
    Nicaise, Claude
    Hehlmann, Rudiger
    Hochhaus, Andreas
    BLOOD, 2006, 108 (11) : 225A - 225A
  • [24] BCR-ABL transcript levels at time of complete cytogenetic remission achieved after salvage with dasatinib or nilotinib
    Mauro, Michael J.
    Press, Richard D.
    Deininger, Michael W.
    Druker, Brian J.
    BLOOD, 2007, 110 (11) : 578A - 578A
  • [25] Bcr-Abl Inhibitory Activities of Imatinib Derivatives
    Hou, Bao-Long
    Yan, Jiaxu
    Liu, Rongrong
    Lv, Longquan
    Feng, Ruirui
    Yang, Xiumei
    Guo, Guanlin
    Wang, Cuiling
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024,
  • [26] Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels
    Gambacorti-Passerini, C
    Piazza, R
    D'Incalci, M
    BLOOD, 2003, 102 (05) : 1933 - 1934
  • [27] Nilotinib, in Comparison to Both Dasatinib and Imatinib, Possesses a Greatly Prolonged Residence Time When Bound to the BCR-ABL Kinase SH1 Domain
    Manley, Paul W.
    Cowan-Jacob, Sandra W.
    Fendrich, Gabriele
    Jahnke, Wolfgang
    Fabbro, Doriano
    BLOOD, 2011, 118 (21) : 727 - 727
  • [28] Are there better Bcr-Abl kinase inhibitors for chronic myeloid leukaemia than imatinib?
    Doggrell, Sheila A.
    Christensen, Anne-Marie
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (01) : 154 - 163
  • [29] Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein
    Elzinga, Baukje M.
    Nyhan, Michelle J.
    Crowley, Lisa C.
    O'Donovan, Tracey R.
    Cahill, Mary R.
    McKenna, Sharon L.
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (06) : 455 - 462
  • [30] IMPACT OF BCR-ABL MUTATIONS ON RESPONSE TO DASATINIB IN ELDERLY CHRONIC MYELOID LEUKEMIA PATIENTS RESISTANT TO IMATINIB
    Tiribelli, M.
    Latagliata, R.
    Breccia, M.
    Luciano, L.
    Castagnetti, F.
    Gozzini, A.
    Cambrin, G. Rege
    Annunziata, M.
    Stagno, F.
    Pregno, P.
    Albano, F.
    Abruzzese, F.
    Musto, P.
    Sora, F.
    Ferrero, D.
    Montefusco, E.
    Cavazzini, F.
    Binotto, G.
    Fanin, R.
    Pane, F.
    Rosti, G.
    Santini, V.
    Fava, C.
    Alimena, G.
    Vigneri, P.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 347 - 347
12345